The clinical takeaways of the RSV immunizations
In the final installment of our RSV Roundtable video series, our panel breaks down the importance of discussing new immunizations with patients now, and how crucial they will be in future RSV seasons.
EUA sought for monoclonal antibody in covid-19 prevention for immunocompromised adults and teens
Biopharmaceutical company, Invivyd, made the request to the FDA for its investigational antibody, VYD222.
RSV Roundtable: What clinicians are witnessing in terms of RSV incidence
Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.
CDC recommends nirsevimab immunization to prevent RSV in infants
The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.
Changing the RSV prevention landscape
From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.
MRNA vaccines efficacious against Omicron infections in children younger than 12
In a large observational study, significant information was obtained about protection against acute infection and disease severity in this age group.
FDA accepts BLA for Pfizer maternal RSV vaccine
The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.
CDC updates vaccination schedule for children and adolescents, includes COVID-19 vaccine
The 2023 changes include vaccines for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.